Introduction and Geographic Availability of New Antibiotics Approved Between 1999 and 2014

Abstract

Despite the urgent need for new, effective antibiotics, few antibiotics of value have entered the market during the past decades. Therefore, incentives have been developed to stimulate antibiotic R&D. For these incentives to be effective, geographic availability for recently approved antibiotics needs to be better understood. In this study, we analyze geographic availability and market introduction of antibiotics approved between 1999 and 2014.

Note: Funding Statement: CK was funded by the DRIVE-AB Consortium, which also partly funded CÅ, JR and RL. DRIVE-AB aims to transform the way policymakers stimulate innovation, sustainable use, and equitable availability of antibiotics to meet unmet public health needs. DRIVE-AB is supported by the IMI Joint Undertaking under the DRIVE-AB grant agreement number 115618, the resources of which are composed of financial contribution from the European Union’s 7th Framework Programme and the European Federation of Pharmaceutical Industries and Associations companies’ in-kind contribution. CÅ was also partly supported by the Research Council of Norway through the Global Health and Vaccination Programme (GLOBVAC), project number 234608. KO is supported by NOA 06-IDSET160030 from the Biomedical Advanced Research and Development Authority (BARDA) under the Assistant Secretary for Preparedness and Response (ASPR) in the US Department of Health and Human Services and an award from the Wellcome Trust. The funders provided support in the form of salaries for authors, according to the statement above, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Declaration of Interests: . This research was partly funded by the DRIVE-AB Consortium, which aims to transform the way policymakers stimulate innovation, sustainable use, and equitable availability of antibiotics to meet unmet public health needs. DRIVE-AB is supported by the IMI Joint Undertaking under the DRIVE-AB grant agreement number 115618, the resources of which are composed of financial contribution from the European Union’s 7th Framework Programme and the European Federation of Pharmaceutical Industries and Associations companies’ in-kind contribution.